News

Aby describes findings from a pair of studies presented at DDW exploring the prevalence and impact of financial burden in liver transplant candidates.

Singh explains a potential new approach to the low FODMAP diet based on findings from research he presented at DDW suggesting a simplified step-up method.

Aflibercept 8 mg exhibited clinically meaningful visual, anatomic improvements at Week 48 in patients with DME regardless of baseline visual acuity.

Semaglutide 1.0 mg reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease, according to the FLOW trial.

Increases in metabolic risk factors like high blood pressure and BMI have led to a 49.4% increase in global disability-adjusted life years from 2000 to 2021.

These findings highlight potential drawbacks of treating psoriasis with phototherapy versus anti-TNFα therapy, though additional research is needed.

Pre-dose IOP outcomes in eyes with DME receiving intravitreal aflibercept 8 mg or 2 mg were comparable and remained stable through Week 48.

This retrospective, systematic review highlighted the lack of studies specifically addressing the needs of patients with inverse psoriasis.

Krugliak Cleveland explains findings from research she presented at DDW comparing intestinal ultrasound and conventional approaches to disease monitoring in IBD.

A systematic review presented at AAPA 2024 showed insignificant differences in treatment outcomes between oral JAK inhibitors and oral steroids based on alopecia outcomes like SALT.

Sisson discusses the adoption of 2021 ATS / ERS guidelines, as well as the need for complementary testing and imagine to contextualize the full pulmonary patient.

Rezaie reviews findings from a prospective clinical trial of a novel palatable elemental diet, highlighting its 100% compliance rate and strong efficacy.

Ji Hyun “CJ” Chun, MPAS, PA-C, BC-ADM, explains the potential value of defining diabetes subtypes based on insulin, obesity and age factors.

Panaccione explains findings from GALAXI 2 and GALAXI 3 demonstrating guselkumab’s superiority to ustekinumab in Crohn’s disease, presented at DDW.

Announced on May 22, 2024, the Roche Diagnostics Tina-quant® Lp(a) assay measures lipoprotein (a) in a person’s bloodstream to evaluate cardiovascular risk.

Swapnil Hiremath, MD, MPH, discusses resistant hypertension, including using an evidence-based approach to management and addressing non-adherence.

These data on genetic correlations allow for new genetic evidence connecting psoriasis and patients’ socioeconomic status.

Joly explains the burden of parenteral support and the significance of new STARS data showcasing apraglutide’s potential in SBS-IF.

Sivers-Teixeira explains that while the care team should quickly expand once dementia has presented in screening, the primary care role stays consistent.

Ashley Malliett, DMSc, MPAS, PA-C, discusses the importance of timely diagnosis and initiated care, as well as contraindications for transplants and LVAD.

A cable-transmission magnetically controlled capsule endoscopy showed comparability to conventional methods in upper GI tract examinations and lesion detection.

Aaron Henry, PA-C, MSHS, discusses why preventive care opportunities are often missed in Black men, and how community-based interventions may help.

Malliett discusses the signs that a caregiver should refer to an HF specialist for advanced care options, including LVAD and heart transplant.

Alkhouri explains survodutide’s mechanism of action as a glucagon/GLP-1 receptor dual agonist and reviews key findings about its use in MASH from the interim analysis.

Data from PREEMPT CRC reveal the blood-based screening test demonstrated a 79.2% sensitivity for detecting colorectal cancer.

At the end of the study period, the median dose of daprodustat and ESA were higher among the ESA-HR cohort when compared with the non-ESA-HR group.

A detailed overview and accompanying quiz on the recommendations made by the AGA in their 2024 guideline on endoscopic eradication

End-of-study results from the phase 3 REGENERATE study were presented at DDW and highlight obeticholic acid’s trend in benefit for clinical outcomes.